<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087669</url>
  </required_header>
  <id_info>
    <org_study_id>ECOH 3</org_study_id>
    <nct_id>NCT03087669</nct_id>
  </id_info>
  <brief_title>Central and Cerebral Circulation in Early Stages After LVAD Implantation</brief_title>
  <acronym>ECOH3</acronym>
  <official_title>Evaluation of Central and Cerebral Circulation in Early Stages After Implantation of Left Ventricular Assist Device (LVAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate patients with a mechanical Left Ventricular Assist Device (LVAD) in
      early stages after surgical implantation. Within the first 2 days of postoperative ICU care,
      20 patients will firstly be exposed to 4 different LVAD pump flow settings with a stable
      blood pressure. A second intervention will be mean arterial blood pressure (MAP) adjustments
      to 4 preset levels (60-70-80 and 90 mmHg) with a constant preset LVAD flow. The two
      manipulations; 1) Constant MAP with variation of LVAD flow and 2) Constant LVAD flow with
      variation of MAP, will be monitored by Central hemodynamic parameters, echocardiographic
      parameters and cerebral blood flow velocity (CBFV) parameters. The purpose of the trial is to
      find the optimal combination of LVAD pump flow, mean arterial pressure and right heart
      ventricle function for each patient. And at the same time describe the effect of flow and
      pressure variations on CBFV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with severe left ventricular heart failure and estimated short expected survival
      time despite optimal medical therapy can be treated with a left ventricular mechanical heart
      pump - described as a Left Ventricular Assist Device (LVAD). The LVAD can be used as a bridge
      for patient survival prior to heart transplantation, or as a destination therapy for terminal
      heart failure. The LVAD delivers a non-pulsatile blood flow into the patients aorta,
      supporting and/or taking over the left ventricular function. However the right heart
      ventricle (RV) is not supported by the LVAD. RV failure is a major threat to the patient, in
      particular during the early postoperative period. Postoperative RV failure after LVAD
      implantation is medically treated, but in severe cases a mechanical temporary right
      ventricular assist (RVAD) may be needed. Patients in need of postoperative RVAD after an LVAD
      implant have a significantly increased mortality. Thus it is of vital importance to balance
      the LVAD pump flow against the native RV function in order to avoid the need for an RVAD. If
      the LVAD flow rate is set too low the RV will be exposed to a high afterload and risk
      failure. If, on the other hand, the LVAD flow is set too high it can potentially completely
      empty the left ventricle with secondary geometrical distortion of the heart chambers and an
      increased venous return to the RV. This too increases the risk for RV failure. To find the
      optimal LVAD flow rate it is custom to do an extensive evaluation of central hemodynamic
      parameters (Cardiac Output(CO), Pulmonary Capillary Wedge Pressure (PCWP), Pulmonary Arterial
      Pressure (PAP), Central Venous Pressure (CVP)) and cardiac echocardiographic evaluation of RV
      function at different LVAD pump flow rates and MAP. The instant balance between RV filling
      pressure-CVP, and LV filling pressure-PCWP, is on the other hand easy to obtain. However it
      is not known if these measurements can be used to obtain an optimal LVAD flow rate.
      Furthermore all mechanically driven circulatory support devices, including LVAD, will expose
      the peripheral arterial circulation to a non-pulsatile blood flow.There are few previous
      reports on how an LVAD affects the cerebral blood flow autoregulation and microembolic load
      at different settings and MAP. This investigation aims to describe these cerebral effect af
      an LVAD using a continous Transcranial Doppler (TCD) detection of cerebral arteries.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>LVAD will have a setting of 4800 rounds per minute (RPM). Hemodynamic, echocardiographic and cerebral blood flow measurements will be performed: CO, PCWP, CVP, PAP, MAP, Peripheral and central hemoglobine oxygen saturation (SaO2 and SvO2), Heart Rate (HR), RV outflow tract Velocity Time Integral (RVOT VTI), RV and LV diameter, VTI of LVAD outflow. CBFV of right and left medial cerebral artery (RMCA and LMCA)
The above mentioned measurements will be repeated with LVAD settings of 5200 RPM, 5600 RPM, and 6000 RPM.
With the LVAD fixed to an optimized setting detected by the previous interventions, the blood pressure will be adjusted to MAP 60 mmHg. The above mentioned measurements will be repeated.
Using Noradrenaline the MAP will be adjusted to 70mmHg, 80 mmHg and 90 mmHg. At steady state for each level of MAP with a fixed LVAD flow, all the above mentioned measurements will be repeatedly performed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes PCWP/CVP ratio</measure>
    <time_frame>Change from baseline at different settings of LVAD RPM within 10 minutes for each level</time_frame>
    <description>The change in PCWP (mmHg)/CVP (mmHg) ratio at different levels of LVAD flow as a marker for the optimal balance between LVAD flow and RV function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CO</measure>
    <time_frame>Change from baseline at different settings of LVAD RPM within 10 minutes for each level</time_frame>
    <description>Cardiac Output in litres/minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVAD Velocity Time Integral</measure>
    <time_frame>Change from baseline at different settings of LVAD RPM within 10 minutes for each level</time_frame>
    <description>LVAD Velocity Time Integral in centimeters(cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricle Outflow Tract (RVOT) Velocity Time Integral (VTI)</measure>
    <time_frame>Change from baseline at different settings of LVAD RPM within 10 minutes for each level</time_frame>
    <description>RVOT Velocity Time Integral in centimeters(cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBFV</measure>
    <time_frame>Change from baseline at different settings of LVAD RPM within 10 minutes for each level</time_frame>
    <description>CBFV in cm/second</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes PCWP/CVP ratio at different MAP</measure>
    <time_frame>Change from baseline at different settings of MAP with a fixed LVAD RPM setting within 10 minutes for each level</time_frame>
    <description>The change in PCWP (mmHg)/CVP (mmHg) ratio at different levels of MAP as a marker for the optimal balance between LVAD flow and RV function</description>
  </other_outcome>
  <other_outcome>
    <measure>LVAD VTI at different MAP</measure>
    <time_frame>Change from baseline at different settings of MAP with a fixed LVAD RPM setting within 10 minutes for each level</time_frame>
    <description>LVAD Velocity Time Integral in centimeters(cm)</description>
  </other_outcome>
  <other_outcome>
    <measure>CO at different MAP</measure>
    <time_frame>Change from baseline at different settings of MAP with a fixed LVAD RPM setting within 10 minutes for each level</time_frame>
    <description>Cardiac Output in litres/minute</description>
  </other_outcome>
  <other_outcome>
    <measure>RVOT VTI at different MAP</measure>
    <time_frame>Change from baseline at different settings of MAP with a fixed LVAD RPM setting within 10 minutes for each level</time_frame>
    <description>RVOT Velocity Time Integral in centimeters(cm)</description>
  </other_outcome>
  <other_outcome>
    <measure>CBFV at different MAP</measure>
    <time_frame>Change from baseline at different settings of MAP with a fixed LVAD RPM setting within 10 minutes for each level</time_frame>
    <description>CBFV in cm/second</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure, Left-Sided</condition>
  <condition>Heart Failure, Right-Sided</condition>
  <arm_group>
    <arm_group_label>Observation of hemodynamic parameters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LVAD flow velocity setting-Rounds Per Minute(RPM) intervention: Change of LVAD RPM while observing Central hemodynamic, echocardiographic and CBFV effects.
MAP intervention: Stepwise Change of MAP from 60-70-80 to 90 mmHg with a fixed set of LVAD RPM. After a 5 minute steady state for each level of MAP, the observations of central hemodynamics, echocardiographic measures and CBFV measurements will be repeated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®</intervention_name>
    <description>Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)</description>
    <arm_group_label>Observation of hemodynamic parameters</arm_group_label>
    <other_name>RPM setting</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAP intervention using Noradrenalin</intervention_name>
    <description>At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin</description>
    <arm_group_label>Observation of hemodynamic parameters</arm_group_label>
    <other_name>MAP setting</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients receiving LVAD of the type HeartMate3® at Sahlgrenska University hospital

        Exclusion Criteria:

          -  Perioperative need for an RVAD first 3 days postoperatively after an LVAD implantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Erik Ricksten, MD.PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bengt Redfors, MD.PhD</last_name>
    <phone>0046313427445</phone>
    <email>bengt.redfors@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bjorn Reinsfelt, MD.PhD</last_name>
    <phone>0046313428183</phone>
    <email>bjorn.reinsfelt@gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital. Department of Cardiothoracic Anaesthesia &amp; Intensive Care</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjorn Reinsfelt, PhD</last_name>
      <phone>0046313428183</phone>
      <email>bjorn.reinsfelt@gu.se</email>
    </contact>
    <contact_backup>
      <last_name>Bengt Redfors, PhD</last_name>
      <phone>0046313427445</phone>
      <email>bengt.redfors@vgregion.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Uriel N, Adatya S, Malý J, Kruse E, Rodgers D, Heatley G, Herman A, Sood P, Berliner D, Bauersachs J, Haverich A, Želízko M, Schmitto JD, Netuka I. Clinical hemodynamic evaluation of patients implanted with a fully magnetically levitated left ventricular assist device (HeartMate 3). J Heart Lung Transplant. 2017 Jan;36(1):28-35. doi: 10.1016/j.healun.2016.07.008. Epub 2016 Jul 17.</citation>
    <PMID>27773456</PMID>
  </results_reference>
  <results_reference>
    <citation>Uriel N, Sayer G, Addetia K, Fedson S, Kim GH, Rodgers D, Kruse E, Collins K, Adatya S, Sarswat N, Jorde UP, Juricek C, Ota T, Jeevanandam V, Burkhoff D, Lang RM. Hemodynamic Ramp Tests in Patients With Left Ventricular Assist Devices. JACC Heart Fail. 2016 Mar;4(3):208-17. doi: 10.1016/j.jchf.2015.10.001. Epub 2015 Dec 30.</citation>
    <PMID>26746378</PMID>
  </results_reference>
  <results_reference>
    <citation>Ono M, Joshi B, Brady K, Easley RB, Kibler K, Conte J, Shah A, Russell SD, Hogue CW. Cerebral blood flow autoregulation is preserved after continuous-flow left ventricular assist device implantation. J Cardiothorac Vasc Anesth. 2012 Dec;26(6):1022-8. doi: 10.1053/j.jvca.2012.07.014.</citation>
    <PMID>23122299</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Bjorn Reinsfelt</investigator_full_name>
    <investigator_title>Head of Department of Cardiac Anesthesia. Consultant. PhD</investigator_title>
  </responsible_party>
  <keyword>Left Ventricular Assist Device</keyword>
  <keyword>Hemodynamic monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

